The Brain Innovation Days hosted its first-ever Pitch Competition during the digital session on January 26. After careful analysis of over 90 applications from start-ups all over Europe, nine finalists went head-to-head to pitch their business in 180 seconds.
PIPRA and icompanion were respectively crowned Jury and Public Awards for Best Pitch.
Both win a free exhibition booth and free access to our physical event to be held in Brussels on October 12 and 13, 2021.
PIPRA also win an in-depth review from all jury members and a one-day workshop provided by beLean.net and our partner imec.istart to work on its business plan, diagnosis, modelling and/or internationalisation (depending on the needs).
Disorientation, memory loss, difficulties in speech. If you are over sixty and about to undergo surgery, you could be at risk of developing any or all these symptoms. Postoperative delirium (POD) is an enormous problem occurring in 20% of surgical patients aged 60+. POD leads to adverse outcomes such as a 25% mortality within one month, double the risk of nursing home admission, is associated with enormous costs to health insurers and 38% of the affected end up suffering long-term cognitive decline and dementia. There are no treatments available once symptoms arise. Instead, the focus is on prevention. Many highly effective prophylactic treatments have been developed but are too costly to deploy for every patient. We are a start-up developing a novel, AI-based pre-operative risk prediction software, trained on the largest database in the world on POD, which highlights patients at risk before undergoing surgery. This patient-centric approach increases patient value by improving health outcomes and decreasing costs over the full cycle of care.
The main goal of icompanion is to give patients with multiple sclerosis (MS) and their treating neurologists more insight into the patient’s disease course by providing an overview of the subclinical (visible on MRI), clinical and self-reported disease activity and comparing it with other patients. The data collected in icompanion will allow the training of prognostic models that are able to test medication virtually. In this way, the neurologist will be able to quickly find the most effective medication for each patient.
In the app, patients can keep track of a lot of relevant information that would otherwise have been lost between doctor’s visits. They can log their daily mood, diary notes, treatments, therapies, and symptoms. They can also perform clinical tests that have been developed by the largest academic centers and that are used worldwide to monitor MS. These tests evaluate their level of disability, cognitive abilities, and fatigue. Furthermore, icompanion also allows patients to upload and view their MRI scans. In this way, they can easily store all their medical scans in one secure and central space. They can scroll through their scans in several directions and learn about what MRI can show (and what it doesn’t).
Unlike most of the other health apps, icompanion is a registered medical device. Hence, the information entered in icompanion by a patient can be used by their doctor to make decisions on their health.
Contact us to get more information: